Author： Poston Walker S Carlos Foreyt John P
Publisher： Informa Healthcare
ISSN： 1465-6566
Source： Expert Opinion on Pharmacotherapy, Vol.5, Iss.3, 2004-03, pp. : 633-642
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
A Benefit-Risk Assessment of Sibutramine in the Management of Obesity
Drug Safety, Vol. 26, Iss. 14, 2003-01 ,pp. :
Access to resources
Recommend
Sibutramine: A Review of its Contribution to the Management of Obesity
Drugs, Vol. 56, Iss. 6, 1998-12 ,pp. :
Sibutramine beneficial in obesity with hyperlipidaemia
Inpharma, Vol. 1, Iss. 1314, 2001-01 ,pp. :
Sibutramine beneficial in adolescent obesity
Inpharma, Vol. 1, Iss. 1383-1384, 2003-01 ,pp. :
NICE issues guidance for sibutramine in obesity
Inpharma, Vol. 1, Iss. 1312, 2001-01 ,pp. :